Peptide LibraryIpamorelin dosage in published studies and labels
These are the doses used for Ipamorelin in FDA labelling and published clinical studies, reported as each source states them, one row per regimen. They describe what was studied or approved for a specific population. They are not a recommendation, and none of them is a dose for any individual.
Research and educational reference only. This is not medical advice, and no figure on this page is a dosing recommendation.
Last checked against primary sources:
Studied regimens and sources
Ipamorelin has been dosed in humans, but only intravenously and not for the purpose it is generally sold for. The published pharmacokinetic study infused 4.21–140.45 nmol/kg over 15 minutes in healthy male volunteers, and two completed phase 2 trials gave it intravenously for post-operative ileus. No published human study supports subcutaneous microgram dosing for growth-hormone or body-composition purposes.
| Human dosing established | Yes |
|---|---|
| Route | Intravenous (in all published human studies) |
| Frequency | Single infusion in the pharmacokinetic study; twice daily in the published ileus trial |
| Duration studied | Single 15-minute infusion (pharmacokinetic study) |
| Half-life | Terminal half-life approximately 2 hours (human, intravenous) |
| Evidence level | Limited Human Evidence |
| Last reviewed | 2026-09-05 |
Research-reported dosing
Doses as studied, one row per regimen. Different trials used different regimens; they are listed separately rather than averaged.
| Study / context | Population | Dose | Route | Frequency | Duration | Outcome studied | Source |
|---|---|---|---|---|---|---|---|
| Human pharmacokinetic and pharmacodynamic study (Gobburu et al., 1999)Clinical trial · Human dose-escalation PK/PD study | Healthy male volunteers, 8 per dose level | 4.21, 14.02, 42.13, 84.27 and 140.45 nmol/kg (dose-escalation) | Intravenous infusion over 15 minutes | Single dose per level | Single 15-minute infusion | Ipamorelin pharmacokinetics and growth hormone release | Gobburu JV et al. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharm Res. 1999. |
| NCT01280344 — phase 2 dose-finding trial, completed 2014, no results postedClinical trial · Phase 2 randomised placebo-controlled trial | Patients recovering gastrointestinal function after surgery (n=320) | 0.03 mg/kg twice daily, 0.06 mg/kg twice daily or 0.06 mg/kg three times daily (dose-finding arms) | Intravenous | — | — | Recovery of gastrointestinal function | NCT01280344 — Safety and Efficacy of Ipamorelin Compared to Placebo for the Recovery of Gastrointestinal Function |
| Phase 2 proof-of-concept trial in post-operative ileus (Beck et al., 2014; NCT00672074)Clinical trial · Phase 2 multicentre double-blind randomised placebo-controlled trial | Adults after small or large bowel resection (117 enrolled, 114 analysed) | 0.03 mg/kg | Intravenous infusion | Twice daily | Postoperative day 1 to day 7, or until discharge | Time to first tolerated solid meal (no significant difference versus placebo, p = 0.15) | Prospective, randomized, controlled, proof-of-concept study of the ghrelin mimetic ipamorelin for the management of postoperative ileus. Int J Colorectal Dis. 2014. |
Where sources disagree
- Every published human study of ipamorelin used intravenous administration. The 200–300 mcg subcutaneous, once-to-three-times-daily protocols published by vendors and reference sites have no published human study behind them, and intravenous and subcutaneous dosing are not interchangeable.
- Doses in the human pharmacokinetic study are reported in nmol/kg and scale with body weight. They are not equivalent to a fixed microgram dose, and this profile does not convert them into one.
- Both completed phase 2 trials were in post-operative ileus, a hospital indication. The first (NCT00672074) was published by Beck et al. in 2014 and found no significant difference from placebo on its efficacy endpoints; the larger dose-finding trial (NCT01280344) has posted no results. There is no published human efficacy evidence for growth-hormone or body-composition use.